Drug-induced Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis: European Regulators' Perspective

    loading  Checking for direct PDF access through Ovid

Abstract

Progressive multifocal leukoencephalopathy (PML) has been associated with the use of a number of multiple sclerosis (MS) immunomodulatory therapies and has assumed a critical place in the evaluation of their benefit/risk. In this review, we discuss the European Union regulatory approach to drug-induced PML in MS, highlight a number of key issues related to the current knowledge on PML, and outline possible paths to help progress the risk management of patients with MS at risk of PML.

Related Topics

    loading  Loading Related Articles